Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem BioAssay

Items: 8

1.

Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Riggins RB, Mazzotta MM, Maniya OZ, Clarke R.

Endocr Relat Cancer. 2010 Aug 16;17(3):R213-31. doi: 10.1677/ERC-10-0058. Print 2010 Sep. Review.

2.

Minireview: the SRC family of coactivators: an entrée to understanding a subset of polygenic diseases?

Lonard DM, Kumar R, O'Malley BW.

Mol Endocrinol. 2010 Feb;24(2):279-85. doi: 10.1210/me.2009-0276. Epub 2009 Oct 21. Review.

3.

Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.

Xu J, Wu RC, O'Malley BW.

Nat Rev Cancer. 2009 Sep;9(9):615-30. doi: 10.1038/nrc2695. Review.

4.

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

Chen FL, Xia W, Spector NL.

Clin Cancer Res. 2008 Nov 1;14(21):6730-4. doi: 10.1158/1078-0432.CCR-08-0581. Review.

5.

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR.

Br J Cancer. 2006 Jun 5;94(11):1604-9.

7.
8.

Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.

Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC.

Cancer Res. 1989 May 15;49(10):2698-702.

Supplemental Content

Support Center